BioSpace News Archive

Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference.

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the approval of once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency.

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company developing novel T cell engagers, announced that management will participate in two upcoming investor conferences in September.

Daré Bioscience, Inc. today announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rules with an institutional investor and an investor affiliated with the licensor of one of the company’s early stage product candidates.

Keros Therapeutics, Inc. , today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences.

Alteogen Inc. (KOSDAQ:196170), a Korean biotech company announced that their recently concluded clinical trial of Tergase® showed zero incidence of ADA (including neutralizing antibodies). Tergase® is Alteogen’s first proprietary product currently under pharmaceutical approval process by the Korean Ministry of Food and Drug Safety.

Kintara Therapeutics, Inc. today announced that it will be presenting a poster at the 2023 European Association for Neuro-Oncology (EANO) Annual Meeting, taking place in Rotterdam, September 21-24, 2023.

InMode Ltd., a leading global provider of innovative medical technologies, announced the participation at the following investor conferences and events in September.

Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, announced the appointment of Robert L. Glanzman, M.D. FAAN, as Chief Medical Officer.

GSK plc and YMCA of the USA will host GSK’s Sideline RSV “Community Conversations” event series as part of their campaign efforts to raise awareness about RSV infection in older adults.